NASDAQ:LXRXLexicon Pharmaceuticals Stock Price, Forecast & News

Lexicon Pharmaceuticals' stock was trading at $2.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, LXRX stock has decreased by 13.7% and is now trading at $1.96.
View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) posted its quarterly earnings results on Thursday, July, 30th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.61) by $0.02. The biopharmaceutical company earned $9.16 million during the quarter, compared to analysts' expectations of $8.70 million. Lexicon Pharmaceuticals had a return on equity of 50.16% and a net margin of 12.26%.
View Lexicon Pharmaceuticals' earnings history.

5 Wall Street analysts have issued 1-year target prices for Lexicon Pharmaceuticals' shares. Their forecasts range from $2.10 to $3.00. On average, they anticipate Lexicon Pharmaceuticals' share price to reach $2.70 in the next year. This suggests a possible upside of 37.8% from the stock's current price.
View analysts' price targets for Lexicon Pharmaceuticals.

Media stories about LXRX stock have trended somewhat negative on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Lexicon Pharmaceuticals earned a news impact score of -1.0 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the next few days.
View the latest news about Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals saw a increase in short interest in July. As of July 15th, there was short interest totaling 11,370,000 shares, an increase of 9.3% from the June 30th total of 10,400,000 shares. Based on an average daily volume of 1,380,000 shares, the days-to-cover ratio is presently 8.2 days. Approximately 11.0% of the company's stock are short sold.
View Lexicon Pharmaceuticals' Current Options Chain.

Some companies that are related to Lexicon Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), Geron (GERN), Orexigen Therapeutics (OREX), Gilead Sciences (GILD), Iovance Biotherapeutics (IOVA) and Micron Technology (MU).

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Lexicon Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wedbush Securities Inc. (0.36%), Strs Ohio (0.22%), Envestnet Asset Management Inc. (0.08%), UBS Group AG (0.03%), ProShare Advisors LLC (0.02%) and Diversified Trust Co (0.02%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats and Sam L Barker.
View institutional ownership trends for Lexicon Pharmaceuticals.

LXRX stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Strs Ohio, Wedbush Securities Inc., Diversified Trust Co, Investors Financial Group LLC, UBS Group AG, and ProShare Advisors LLC. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, and Sam L Barker.
View insider buying and selling activity for Lexicon Pharmaceuticals.

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of LXRX stock can currently be purchased for approximately $1.96.

Lexicon Pharmaceuticals has a market capitalization of $209.94 million and generates $322.07 million in revenue each year. The biopharmaceutical company earns $130.13 million in net income (profit) each year or $1.35 on an earnings per share basis. Lexicon Pharmaceuticals employs 202 workers across the globe.

The official website for Lexicon Pharmaceuticals is www.lexpharma.com.

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.